Efficacy and safety of convalescent plasma therapy in SARS-CoV2 patients on hemodialysis.

Autor: Sajmi S; Institute of Nephrology, Madras Medical College, Rajiv Gandhi Government General Hospital, Park Town, Chennai, Tamil Nadu, India., Goutham K; Institute of Nephrology, Madras Medical College, Rajiv Gandhi Government General Hospital, Park Town, Chennai, Tamil Nadu, India., Arumugam V; Institute of Nephrology, Madras Medical College, Rajiv Gandhi Government General Hospital, Park Town, Chennai, Tamil Nadu, India., Gopalakrishnan N; Institute of Nephrology, Madras Medical College, Rajiv Gandhi Government General Hospital, Park Town, Chennai, Tamil Nadu, India., Lamech TM; Institute of Nephrology, Madras Medical College, Rajiv Gandhi Government General Hospital, Park Town, Chennai, Tamil Nadu, India., Aiswarya D; Institute of Nephrology, Madras Medical College, Rajiv Gandhi Government General Hospital, Park Town, Chennai, Tamil Nadu, India., Krishna R; Institute of Nephrology, Madras Medical College, Rajiv Gandhi Government General Hospital, Park Town, Chennai, Tamil Nadu, India., Vathsalyan P; Institute of Nephrology, Madras Medical College, Rajiv Gandhi Government General Hospital, Park Town, Chennai, Tamil Nadu, India., Kannan BS; Institute of Nephrology, Madras Medical College, Rajiv Gandhi Government General Hospital, Park Town, Chennai, Tamil Nadu, India., Solomon D; Institute of Nephrology, Madras Medical College, Rajiv Gandhi Government General Hospital, Park Town, Chennai, Tamil Nadu, India., Nithya G; Institute of Nephrology, Madras Medical College, Rajiv Gandhi Government General Hospital, Park Town, Chennai, Tamil Nadu, India., Sastry BVRH; Institute of Nephrology, Madras Medical College, Rajiv Gandhi Government General Hospital, Park Town, Chennai, Tamil Nadu, India., Sakthirajan R; Institute of Nephrology, Madras Medical College, Rajiv Gandhi Government General Hospital, Park Town, Chennai, Tamil Nadu, India.
Jazyk: angličtina
Zdroj: Hemodialysis international. International Symposium on Home Hemodialysis [Hemodial Int] 2021 Oct; Vol. 25 (4), pp. 515-522. Date of Electronic Publication: 2021 Jun 16.
DOI: 10.1111/hdi.12951
Abstrakt: Background: The passive immunization of patients with SARS-CoV2 with convalescent plasma (CP) is theoretically beneficial in patients with end-stage renal disease who are immunosuppressed and unable to mount an adequate immune response. Hence, this study was conducted to evaluate the safety and efficacy of CP in patients with chronic kidney disease on hemodialysis with moderate-to-severe SARS-CoV2 infection.
Methods: A prospective observational cohort study was conducted in consecutive 68 moderate-to-severe SARS-CoV2 infected patients who were on maintenance hemodialysis or with acute worsening of chronic kidney disease which required initiation of hemodialysis. Patients who received CP were compared with those who did not. The primary outcome was death during hospitalization. Clinical characteristics, duration of hospitalization and inflammatory parameters were compared between the two groups. A subgroup analysis was done to find whether early initiation of plasma was associated with better outcome.
Results: Sixteen patients (44%) in the plasma group and 14 (45%) patients in the control group died during hospitalization (p = 0.95). The median duration of hospitalization was 9 (6-14) days in the plasma group and 9 (6-16) in the control group (p = 0.60). There was no difference in mortality or duration of hospitalization with respect to early initiation of CP (p = 0.29). Fistula thrombosis occurred in two patients (11.1%) in the plasma group.
Conclusion: Therapy with CP does not appear to confer any clinical benefit in moderate-to-severe SARS-CoV-2 infected patients with chronic kidney disease on hemodialysis.
(© 2021 International Society for Hemodialysis.)
Databáze: MEDLINE
Externí odkaz: